Starling Oncology, Inc. (STLN)
NASDAQ: STLN · Real-Time Price · USD
6.71
-0.20 (-2.89%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Starling Oncology Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 587.24 | 502.73 | 393.41 | 324.24 | 252.48 | 203 |
Revenue Growth | 38.38% | 27.79% | 21.33% | 28.42% | 24.37% | 8.26% |
Gross Profit Gross Profit Growth | 92.17 | 76.44 | 54 | 59.57 | 52.09 | 40.85 |
Operating Income Operating Income Growth | -26.09 | -36.08 | -60.12 | -60.15 | -72.01 | -45.38 |
Net Income Net Income Growth | -30.56 | -50.31 | -53.01 | -67.88 | 0.07 | -10.63 |
Earnings Per Share EPS Growth | -0.30 | -0.54 | -0.71 | -0.92 | -0.21 | -0.16 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Patient Services Patient Services Growth | 237.95 | 228.99 | 204.88 | 213.5 | 166.79 | 124.07 |
Specialty Pharmacy Specialty Pharmacy Growth | 343.46 | 269.18 | 179.92 | 103.84 | 79.34 | 72.55 |
Clinical Trials & Other Clinical Trials & Other Growth | 5.84 | 4.56 | 8.61 | 6.9 | 6.36 | 6.38 |
Total Total Growth | 587.24 | 502.73 | 393.41 | 324.24 | 252.48 | 203 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 41.09 | 33.57 | 49.67 | 82.86 | 73.81 | 114.3 |
Total Debt Total Debt Growth | 104.79 | 104.55 | 123.92 | 119.68 | 108.18 | 0.18 |
Net Cash (Debt) Net Cash Growth | -63.7 | -70.98 | -74.25 | -36.82 | -34.37 | 114.12 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.63 | -0.77 | -0.99 | -0.50 | -0.43 | 1.72 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 0.33 | -24.59 | -26.54 | -36.32 | -61.76 | -32.68 |
Capital Expenditures CapEx Growth | -3.61 | -3.2 | -3.79 | -4.57 | -5.53 | -2.85 |
Free Cash Flow Free Cash Flow Growth | -3.29 | -27.79 | -30.33 | -40.88 | -67.29 | -35.53 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 15.69% | 15.20% | 13.73% | 18.37% | 20.63% | 20.12% |
Operating Margin | -4.44% | -7.18% | -15.28% | -18.55% | -28.52% | -22.36% |
Pretax Margin | -6.18% | -12.08% | -16.44% | -25.63% | -0.04% | -5.71% |
Profit Margin | -5.20% | -10.01% | -13.47% | -20.93% | 0.03% | -5.24% |
FCF Margin | -0.56% | -5.53% | -7.71% | -12.61% | -26.65% | -17.50% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 1805.81 | - |
PS Ratio | 1.16 | 0.70 | 0.06 | 0.46 | 0.49 | 3.52 |